All In Biotech

NDA 019921 · Allergan

Ocuflox

Ofloxacin · Ophthalmic · Quinolone Antimicrobial

Last checked: Nov 20, 2026Latest source record: Nov 16, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Jul 30, 1993

Approved uses

2

Original approval plus efficacy supplements

Registered trials

404

122 Phase 3, 26 recruiting

FAERS reports

7,237

5,537 serious, 615 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 13, 2024.

INDICATIONS AND USAGE OCUFLOX ® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OCUFLOX · OFLOXACIN 0.3% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Ofloxacin" as an intervention, any sponsor and status, largest first.

All 404 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain366
  • drug ineffective349
  • off label use318
  • headache291
  • pain274
  • fatigue272
  • arthralgia260
  • nausea257
  • diarrhoea252
  • acute kidney injury248
  • anxiety215
  • pyrexia213

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004131
2005103
200698
200796
2008111
2009141
201093
2011203
2012242
2013151
2014154
2015218
2016289
2017375
2018531
2019594
2020546
2021582
2022617
2023640
2024508
2025499
2026314

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ocuflox (Ofloxacin)

2024 spending

$7K

Beneficiaries

62

73 claims

Per beneficiary

$108

$15.01 per unit

View as table
YearSpending
2020$6,885
2021$7,765
2022$9,166
2023$5,664
2024$6,679

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 728 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.